Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1853 1
1873 1
1875 1
1877 6
1881 1
1885 2
1886 1
1887 3
1888 3
1889 2
1890 3
1891 2
1892 1
1895 2
1896 2
1897 6
1898 3
1900 1
1901 1
1903 1
1904 1
1905 4
1908 2
1909 10
1910 5
1911 14
1912 3
1913 11
1914 3
1915 5
1916 14
1917 8
1918 10
1919 3
1920 4
1921 7
1922 19
1923 29
1924 17
1925 21
1926 13
1927 20
1928 14
1929 21
1930 20
1931 24
1932 26
1933 19
1934 32
1935 36
1936 29
1937 25
1938 32
1939 21
1940 24
1941 10
1942 15
1943 15
1944 16
1945 649
1946 2239
1947 2246
1948 2530
1949 1631
1950 219
1951 2978
1952 6697
1953 8102
1954 8413
1955 9062
1956 9464
1957 10057
1958 9778
1959 10377
1960 11375
1961 12057
1962 8206
1963 6377
1964 15244
1965 20297
1966 27006
1967 32597
1968 36387
1969 39955
1970 42052
1971 45217
1972 48950
1973 52178
1974 55866
1975 56625
1976 56882
1977 57986
1978 60713
1979 64076
1980 65542
1981 67281
1982 71945
1983 75286
1984 78177
1985 80747
1986 82994
1987 86509
1988 93169
1989 100236
1990 105507
1991 105686
1992 106722
1993 108653
1994 111830
1995 115106
1996 115936
1997 117119
1998 119908
1999 122443
2000 130797
2001 138673
2002 146175
2003 154754
2004 160112
2005 170866
2006 180656
2007 188521
2008 196249
2009 202997
2010 216700
2011 232309
2012 241795
2013 248870
2014 254514
2015 259517
2016 256392
2017 258753
2018 265245
2019 270764
2020 277081
2021 269097
2022 249772
2023 226000
2024 260443
2025 21059

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,596,745 results

Results by year

Filters applied: . Clear all
Page 1
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development.
Liao MZ, Leipold DD, Chen SC, Li Z, Kamath AV, Li C. Liao MZ, et al. Xenobiotica. 2024 Aug;54(8):543-551. doi: 10.1080/00498254.2024.2351044. Epub 2024 Sep 27. Xenobiotica. 2024. PMID: 38738473 Free article. Review.
Given the complex molecular structures of ADCs, combining the molecular characteristics of small-molecule drugs and those of large-molecule biotherapeutics, there are several unique considerations when designing nonclinical-to-clinical PK/PD translation strategies.This com …
Given the complex molecular structures of ADCs, combining the molecular characteristics of small-molecule drugs and those of large-molecule …
Pd-based nanoparticles: Plant-assisted biosynthesis, characterization, mechanism, stability, catalytic and antimicrobial activities.
Nasrollahzadeh M, Sajjadi M, Dadashi J, Ghafuri H. Nasrollahzadeh M, et al. Adv Colloid Interface Sci. 2020 Feb;276:102103. doi: 10.1016/j.cis.2020.102103. Epub 2020 Jan 9. Adv Colloid Interface Sci. 2020. PMID: 31978638 Review.
Among various metal nanoparticles, palladium nanoparticles (Pd NPs) are one of the most important and fascinating nanomaterials. An important concern about the preparation of Pd NPs is the formation of toxic by-products, dangerous wastes and harmful pollutants. ...T …
Among various metal nanoparticles, palladium nanoparticles (Pd NPs) are one of the most important and fascinating nanomaterials. An i …
Emerging targets for anticancer vaccination: PD-1.
Tobias J, Steinberger P, Drinić M, Wiedermann U. Tobias J, et al. ESMO Open. 2021 Oct;6(5):100278. doi: 10.1016/j.esmoop.2021.100278. Epub 2021 Oct 11. ESMO Open. 2021. PMID: 34649221 Free PMC article. Review.
Among the mechanisms by which tumor cells escape the immune surveillance, one is the interaction between programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1). Inhibition of the PD-1/PD-L1 pathway with monoclonal antib …
Among the mechanisms by which tumor cells escape the immune surveillance, one is the interaction between programmed cell death protein 1 ( …
N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy.
Luo P, Li S, Long X. Luo P, et al. Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188873. doi: 10.1016/j.bbcan.2023.188873. Epub 2023 Feb 24. Biochim Biophys Acta Rev Cancer. 2023. PMID: 36842764 Review.
Therefore, identifying the underlying modulators of the PD-1/PD-L1 pathway to completely comprehend the mechanisms of anti-PD-1/PD-L1 treatment is crucially important. ...We also reviewed m6A-associated lncRNAs in the regulation of the PD-1/P …
Therefore, identifying the underlying modulators of the PD-1/PD-L1 pathway to completely comprehend the mechanisms of anti- …
Combination Strategies PD-1/PD-L1 Antagonists.
Sznol M. Sznol M. Cancer J. 2018 Jan/Feb;24(1):54-57. doi: 10.1097/PPO.0000000000000304. Cancer J. 2018. PMID: 29360729 Review.
Despite the broad clinical antitumor activity of PD-1/PD-L1 antagonists, many patients who are treated with these agents either do not respond or achieve suboptimal responses. ...Many combination trials have been initiated in patients with or without prior exposure …
Despite the broad clinical antitumor activity of PD-1/PD-L1 antagonists, many patients who are treated with these agents eithe …
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X, Lu X, Luo G, Xiang H. Lin X, et al. Eur J Med Chem. 2020 Jan 15;186:111876. doi: 10.1016/j.ejmech.2019.111876. Epub 2019 Nov 15. Eur J Med Chem. 2020. PMID: 31761384 Review.
However, no small-molecule inhibitors have been approved so far, indicating a challenging process of developing marketable small-molecule PD-1/PD-L1 targeted therapeutics. This review will summarize and provide insight into recent advances in the PD-1/PD …
However, no small-molecule inhibitors have been approved so far, indicating a challenging process of developing marketable small-molecule …
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X. Ai L, et al. Drug Des Devel Ther. 2020 Sep 8;14:3625-3649. doi: 10.2147/DDDT.S267433. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32982171 Free PMC article. Review.
PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. ...Our review discussed the mechanism of action of PD-1/PD-L1 inhibitors and presented clinical trials of currently approved PD …
PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. ...Our …
Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R, Yuan D, Ma J. Chen R, et al. Future Med Chem. 2022 Jan;14(2):97-113. doi: 10.4155/fmc-2021-0256. Epub 2021 Dec 6. Future Med Chem. 2022. PMID: 34870447 Review.
Immunotherapy inhibiting the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) interaction has emerged as one of the most attractive cancer treatment strategies. ...The development of small-molecule inhibitors targeting PD-1/PD-L1 interaction i …
Immunotherapy inhibiting the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) interaction has emerged as one of the m …
Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy.
Jiao P, Geng Q, Jin P, Su G, Teng H, Dong J, Yan B. Jiao P, et al. Curr Pharm Des. 2018;24(41):4911-4920. doi: 10.2174/1381612824666181112114958. Curr Pharm Des. 2018. PMID: 30417781 Review.
Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficacy in various cancer models. Current PD-1/PD-L1 modulators approved by FDA are exclusively dominated by therapeutic antibodies. …
Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficac …
An updated patent review on PD-1/PD-L1 antagonists (2022-present).
Uzar W, Kaminska B, Rybka H, Skalniak L, Magiera-Mularz K, Kitel R. Uzar W, et al. Expert Opin Ther Pat. 2024 Aug;34(8):627-650. doi: 10.1080/13543776.2024.2368237. Epub 2024 Jun 25. Expert Opin Ther Pat. 2024. PMID: 38903044 Free article. Review.
INTRODUCTION: PD-L1, via its interactions with PD-1, constitutes a key immune checkpoint that allows cancer cells to escape immune surveillance. Targeting PD-1/PD-L1 with monoclonal antibodies (mAbs) led to spectacular success in clinical oncology. ...
INTRODUCTION: PD-L1, via its interactions with PD-1, constitutes a key immune checkpoint that allows cancer cells to escape im …
7,596,745 results
You have reached the last available page of results. Please see the User Guide for more information.